Skip to main content
Journal of Translational Medicine logoLink to Journal of Translational Medicine
letter
. 2020 Dec 14;18:486. doi: 10.1186/s12967-020-02668-3

Survival differences by ethnicity among patients diagnosed with bladder cancer

Boda Guo 1,2, Ming Liu 1,2,
PMCID: PMC7737256  PMID: 33317562

Dear Editor,

We read the study by Fang et al. [1] with great interest and would like to congratulate the authors for their superb study. The authors compared the oncologic outcomes of bladder cancer (BC) of different ethnicities, which may aid in clinical decision-making. As such, there are a few points that we would like to bring up.

  1. Their study included patients with primary BC but did not exclude multiple primary cancers. However, another SEER-based study showed BC patients were at a significantly higher risk of developing a second malignancy, which may affect patients’ survival [2].

  2. BC surgery in the SEER database includes transurethral resection of bladder, partial cystectomy and complete cystectomy, etc. It would be more meaningful to stratify patients according to the type of surgery that they received; in this way, readers can easily see which surgical treatment improves BC patient’s survival better.

  3. Some of the patients included in the analysis received radiotherapy or chemotherapy. These two types of treatment should be taken into consideration since prior studies showed that both radiotherapy and chemotherapy hold great potential in the management of BC patients [3, 4].

Acknowledgements

None.

Disclaimers

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Abbreviation

BC

Bladder cancer

Authors’ contributions

BG reviewed the relevant study and drafted this letter. ML revised this letter for critical content and scientific rigour. Both authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145. doi: 10.1186/s12967-020-02308-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma—a population-based study. Anticancer Res. 2017;37(4):2033–2036. doi: 10.21873/anticanres.11548. [DOI] [PubMed] [Google Scholar]
  • 3.Diaz DA, Pollack A, Reis IM, Mahmoud O, Gonzalgo ML, Ishkanian A, et al. Neoadjuvant radiotherapy improves survival in patients with T2b/T3 bladder cancer: a population-based analysis. Clin Genitourin Cancer. 2015;13(4):378–384. doi: 10.1016/j.clgc.2015.02.014. [DOI] [PubMed] [Google Scholar]
  • 4.Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34(8):825–832. doi: 10.1200/JCO.2015.64.1076. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from Journal of Translational Medicine are provided here courtesy of BMC

RESOURCES